Schindel Yair Chaim 4
4 · Adicet Bio, Inc. · Filed Sep 17, 2020
Insider Transaction Report
Form 4
Adicet Bio, Inc.ACET
Schindel Yair Chaim
Director
Transactions
- Award
Non-Qualified Stock Option (right to buy)
2020-09-17+30,000→ 30,000 totalExercise: $16.11Exp: 2030-09-16→ Common Stock (30,000 underlying) - Award
Common Stock
2020-09-15+1,104,460→ 1,104,460 total(indirect: By Partnership)
Footnotes (3)
- [F1]The reporting person is the sole shareholder of aMoon General Partner Ltd., which is the sole general partner of aMoon 2 Fund G.P. Limited Partnership, which is the sole general partner of aMoon 2 Fund Limited Partnership, which directly holds the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F2]Received in exchange for shares of Series B Preferred Stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, the closing share price of a share of resTORbio common stock was $2.28 per share. On the effective date of the Merger, resTorbio changed its name to "Adicet Bio, Inc."
- [F3]The shares of common stock subject to the option shall vest in equal installments on each of the thirty-six (36) monthly anniversaries of the vesting commencement date, provided that the reporting person remains in continuous service as of the applicable vesting date.